Overview
Align Q2 2025 revenue down 1.6% yr/yr, missing analyst expectations
Adjusted EPS for Q2 2025 misses consensus, reflecting challenges in Clear Aligner sales
Company plans to streamline operations and reduce workforce, incurring one-time charges of $150 mln to $170 mln
Outlook
Align expects Q3 revenue between $965 mln and $985 mln
Company anticipates Q3 GAAP gross margin of 64% to 65%
Align forecasts fiscal 2025 Clear Aligner volume growth in low-single digits
Company sees 2025 GAAP operating margin at 13% to 14%
Result Drivers
FOREIGN EXCHANGE IMPACT - Revenues favorably impacted by foreign exchange, contributing $26.4 mln sequentially and $5.6 mln yr/yr
CLEAR ALIGNER CHALLENGES - Lower-than-expected volumes in Europe and North America led to a decrease in Clear Aligner revenues yr/yr
IMAGING SYSTEMS GROWTH - Strong sales of iTero Lumina scanner wand upgrades drove sequential and yr/yr growth in Imaging Systems and CAD/CAM Services
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Miss | $1.01 bln | $1.06 bln (11 Analysts) |
Q2 Adjusted EPS | Miss | $2.49 | $2.57 (12 Analysts) |
Q2 EPS |
| $1.72 |
|
Q2 Adjusted Net Income | Miss | $181.10 mln | $188.20 mln (10 Analysts) |
Q2 Net Income |
| $124.60 mln |
|
Q2 Adjusted Operating Income | Miss | $215.90 mln | $228.70 mln (11 Analysts) |
Q2 Adjusted Operating Margin |
| 21.3% |
|
Q2 Gross Profit |
| $708.12 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 5 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Align Technology Inc is $245.50, about 16.2% above its July 29 closing price of $205.81
The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 16 three months ago
Press Release: ID:nBw4Lgxx8a